O

    OmniAb Inc. (OABI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.38
    -0.09 (-2.01%)

    Market Cap: $649.89M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(9/15)
    Avg Surprise
    +19.84%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.14 - $-0.12
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate Drift
    90d ago$-0.12+9.6%
    60d ago$-0.12+9.6%
    30d ago$-0.12+9.6%
    7d ago$-0.13+0.0%
    Current$-0.13
    Revenue Consensus
    $3M
    Range$3M - $4M
    7 analysts
    Dec 31, 2026
    EPS Consensus$-0.01
    Range$-0.04 - $0.01
    5 analysts
    Revenue Consensus
    $21M
    Range$19M - $23M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.01---
    Sep 26EST
    		-$-0.13---
    Jun 26
    		$-0.05N/A+54.55%Beat+66.7%
    Mar 26
    		$-0.06$-0.10+40.00%Beat+64.7%
    Dec 25
    		$-0.11$-0.09-25.71%Miss+8.3%
    Sep 25
    		$-0.14$-0.14+0.00%Beat+12.5%
    Jun 25
    		$-0.15$-0.15+0.00%Beat-15.4%
    Mar 25
    		$-0.17$-0.17+0.00%Beat+10.5%
    Dec 24
    		$-0.12$-0.10-24.10%Miss+14.3%
    Sep 24
    		$-0.16$-0.14-14.29%Miss+0.0%
    Jun 24
    		$-0.13$-0.17+23.53%Beat+13.3%
    Mar 24
    		$-0.19$-0.16-18.75%Miss-216.7%
    Dec 23
    		$-0.14$-0.15+6.67%Beat-300.0%
    Sep 23
    		$-0.16$-0.13-23.08%Miss-77.8%
    Jun 23
    		$-0.15$-0.12-25.00%Miss-150.0%
    Mar 23
    		$-0.06N/A+53.85%Beat+62.5%
    Dec 22
    		$0.07$0.02+250.00%Beat+800.0%
    Sep 22
    		$-0.09$0.00N/AMiss-800.0%
    Jun 22
    		$-0.06N/AN/ABeat-
    Mar 22
    		$-0.16N/AN/ABeat-
    Dec 21
    		$-0.01N/AN/ABeat-
    Sep 21
    		$-0.01N/AN/ABeat-
    Jun 21
    		$0.00$0.00N/ABeat-
    Mar 21
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-12.17EV/EBITDA-10.62x
    Price/FCF-31.10xFCF Yield-3.22%
    Profitability
    Profit Margin-115.10%Operating Margin-49.50%
    ROE-17.00%ROIC-17.91%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio4.80xQuick Ratio4.80x
    Trading Statistics
    Beta1.22Avg Volume2.23M
    52-Week High$4.9352-Week Low$1.30

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.44
    SMA 20$3.73
    SMA 50$2.81
    SMA 200$2.10
    EMA 10$4.31
    EMA 20$3.85
    EMA 50$3.11
    EMA 200$2.33

    MACD

    Line: 0.58Signal: 0.55Hist: 0.04

    ADX

    ADX: 58.5+DI: 38.7-DI: 10.9

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down16.0
    PSAR$4.92

    Bollinger Bands

    Upper Band$5.49
    Lower Band$1.97
    %B Position9455%(Upper)
    Band Width0.69

    RSI (14-Day)

    Overbought
    71.6

    Momentum Oscillators

    Stoch %K73.9
    Stoch %D83.0
    Williams %R-33.7
    ROC (10d)14.7%
    Momentum0.56
    CCI (20d)61.3
    MFI (14d)83.4

    Volatility Measures

    ATR (14d)$0.28(6.3%)
    StdDev (20d)0.88
    Hist Vol144.8%(High)

    Volume Flow

    VWAP$4.39
    OBV39.6M
    AD Line-7.3M
    CMF (20d)-0.149

    Volume Metrics

    Avg Vol (20d)2.3M
    Vol Ratio0.5x
    VWMA (20d)$3.90

    Pivot Points

    R3$4.73
    R2$4.65
    R1$4.56
    Pivot Point$4.49
    S1$4.40
    S2$4.32
    S3$4.23

    Advanced Oscillators

    TSI63.95
    Ultimate Osc54.7
    KST960.16

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$13.41M$14.43M$8.38M$2.24M$3.90M$4.15M$10.80M$4.17M$7.61M$3.80M$4.82M$5.48M
    Cost of Revenue$610,000$15,000$12,000$29,000$262,000$3,000$11.05M$0$0$0$4.93M$0
    Gross Profit$12.80M$14.41M$8.36M$2.21M$3.63M$4.15M$10.80M$4.17M$7.61M$3.80M$4.82M$5.48M
    Operating Expenses$19.44M$22.24M$24.13M$20.35M$19.85M$23.00M$26.68M$23.94M$23.92M$26.35M$26.03M$25.79M
    R&D$9.59M$9.64M$13.91M$10.38M$10.86M$12.60M$13.31M$13.32M$13.94M$14.55M$14.77M$13.87M
    SG&A$6.65M$6.62M$6.84M$6.78M$7.68M$7.92M$7.36M$7.08M$7.96M$8.34M$7.87M$8.51M
    Operating Income$-6,637,000$-7,829,000$-15,766,000$-18,140,000$-16,219,000$-18,844,000$-15,880,000$-19,764,000$-16,305,000$-22,553,000$-21,206,000$-20,315,000
    Interest Income$434,000$487,000$1.23M$462,000$436,000$537,000$655,000$691,000$785,000$975,000$1.18M$1.26M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-6,212,000$-7,265,000$-14,546,000$-17,686,000$-15,756,000$-18,306,000$-15,223,000$-19,081,000$-15,529,000$-21,578,000$-20,028,000$-19,042,000
    Income Tax Expense$-353,000$442,000$-367,000$-1,161,000$119,000$-106,000$-2,155,000$-2,708,000$-1,898,000$-2,617,000$-5,975,000$-3,304,000
    Net Income$-5,859,000$-7,707,000$-14,179,000$-16,525,000$-15,875,000$-18,200,000$-13,068,000$-16,373,000$-13,631,000$-18,961,000$-14,053,000$-15,738,000
    EBITDA$-2,573,000$-737,000$-8,308,000$-13,665,000$-11,746,000$-14,339,000$-8,485,000$-15,131,000$-10,590,000$-18,226,000$-17,062,000$-16,291,000
    EBIT$-6,646,000$-7,752,000$-15,771,000$-18,148,000$-16,192,000$-18,843,000$-15,878,000$-19,772,000$-16,314,000$-22,553,000$-21,206,000$-20,307,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OABI

    News

    OmniAb (NASDAQ:OABI) Passes Minervini Trend Template and High-Growth Momentum Screen

    OmniAb (NASDAQ:OABI) has passed both the Minervini Trend Template and a high-growth momentum screen, indicating strong technical and accelerating fundamental performance. The drug discovery company shows positive short-term and long-term trends, with significant EPS and revenue growth in recent quarters. Despite a high technical rating, the setup rating is low due to recent volatility, and the company still faces fundamental risks including negative free cash flow and uneven revenue on a trailing basis.

    ChartMill•8/22/26•
    Bullish

    Why Is Omniab Stock Rallying After Eli Lilly Deal?

    OmniAb, Inc. (NASDAQ: OABI) shares surged after the company announced a global collaboration and license agreement with Eli Lilly and Company (NYSE: LLY) for an ion channel program. The deal includes an upfront payment and up to $370 million in potential milestone payments, along with tiered royalties. OmniAb also raised its 2026 cash outlook due to recent licensing activity, now expecting $49 million to $53 million in cash and cash equivalents.

    TradingView•8/18/26•
    Bullish

    OmniAb partners with Eli Lilly on ion channel program

    OmniAb, Inc. has announced a global collaboration and license agreement with Eli Lilly and Company for an ion channel drug discovery program. Under the agreement, OmniAb will receive an upfront payment and is eligible for up to $370 million in milestone payments, plus tiered royalties on global net sales. The collaboration will leverage OmniAb's technology platform and expertise in ion channel discovery and screening for therapeutic development.

    Investing.com•8/18/26•
    Bullish

    OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook

    OmniAb Inc. (OABI) shares surged nearly 18% after the company increased its 2026 cash forecast due to new licensing agreements, including one with Eli Lilly for its ion-channel program. This improved outlook provides OmniAb with greater financial stability, reducing immediate dilution risks and enabling continued investment in its antibody discovery technologies. The key challenge for OmniAb remains translating its platform into substantial long-term licensing fees and milestones to maintain its cash position.

    TradingView•8/17/26•
    Bullish

    Eli Lilly Signs $370 Million Ion Channel Deal With OmniAb, Sending Shares Surging

    Eli Lilly has inked a global collaboration and license agreement with OmniAb for a new ion channel program, a deal potentially worth up to $370 million in milestone payments and tiered royalties. The news sent OmniAb's shares surging in premarket trading. OmniAb also updated its 2026 cash outlook upward due to recent licensing activity.

    BigGo Finance•8/17/26•
    Neutral

    Frequently Asked Questions About OABI

    Does OABI pay dividends?
    OmniAb Inc. (OABI) does not currently pay a regular dividend.
    What is OABI's market cap?
    OmniAb Inc. (OABI) has a market capitalization of $649.89M with a current stock price of $4.38.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In